Skip to main content
TipRanks
Go Ultimate75% OFF

Xeris Pharmaceuticals (2B30) Drug Pipeline

0 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Levothyroxine SodiumHypothyroidismPhase IICompletedStudy of XP-8121 For the Treatment of Adult Subjects With HypothyroidismMar 28, 2023―
Pram9, Regular Insulin + Pramlintide, Regular InsulinDiabetes Mellitus, Type 1, Insulin-Dependent Diabetes MellitusPhase IICompletedPhase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1DAug 28, 2019―
Glucagon Rtu Injection With Insulin Pump Reduction, Vehicle For Glucagon Rtu Injection With Insulin Pump Reduction, Glugaon Rtu Injection Without Insulin Pump ReductionHypoglycemiaPhase IICompletedGlucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1DFeb 12, 2019―
Glucagon RtuHyperinsulinemic HypoglycemiaPhase IICompletedGlucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric SurgeryDec 07, 2018―
G-Pen, Novo GlucagonType 1 Diabetes Mellitus, Insulin Hypoglycemia, Severe HypoglycemiaPhase IIICompletedG-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 DiabetesNov 08, 2018―
GlucagonDiabetes Mellitus, Type 1, Hypoglycemia UnawarenessPhase IITerminatedGlucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory ResponsesMar 25, 2018―
G-Pen, Lilly GlucagonType 1 Diabetes Mellitus, Insulin Hypoglycemia, Severe HypoglycemiaPhase IIICompletedG-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 DiabetesFeb 13, 2018―
GlucagonDiabetes Mellitus, Type 1Phase IIICompletedGlucose Response of G-Pen (Glucagon Injection) in Pediatric T1D PatientsMar 16, 2017―
GlucagonCongenital HyperinsulinismPhase IICompletedCSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital HyperinsulinismOct 14, 2016―
G-Pump™ (Glucagon Infusion)Hypoglycemia, Complications Of Bariatric ProceduresPhase IICompletedDelivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery PatientsMar 30, 2016―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Xeris Pharmaceuticals (DE:2B30) have in its pipeline
Xeris Pharmaceuticals DE:2B30 is currently developing the following drugs: Levothyroxine Sodium, Pram9, Regular Insulin + Pramlintide, Regular Insulin, Glucagon Rtu Injection With Insulin Pump Reduction, Vehicle For Glucagon Rtu Injection With Insulin Pump Reduction, Glugaon Rtu Injection Without Insulin Pump Reduction, Glucagon Rtu, G-Pen, Novo Glucagon, Glucagon, G-Pen, Lilly Glucagon, G-Pump™ (Glucagon Infusion), G-Pen (Glucagon Injection), Lilly Glucagon (Glucagon Injection [Rdna Origin]), Novo Nordisk Glucagen®, G-Pump™ (Glucagon Infusion), G-Pen Mini™ (Glucagon Injection), G-Pen(Tm) 1 Mg, Lilly Glucagon(Tm) 1 Mg, G-Pen(Tm) 0.5 Mg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.